CHAWNSHANG CHANG; (U.S.A. Citizen)

Office Address: 601 Elmwood Ave. Box 626, University of Rochester, Rochester, NY 14642

           (Tel:585-2759994; Fax:585-7564133; E-Mail: chang@urmc.rochester.edu)

 

Education: 

 

1974-1978      National Taiwan University  (B.S.)       Agriculture Chemistry

1978-1980      Army Chemical School  (R.O.T.C.)      Nuclear Chemistry & Biology

1980-1985      University of Chicago  (Ph.D.)      Biochemistry & Molecular Biology

1985-1988      University of Chicago  (Post Dr.)      Molecular Endocrinology

 

Academic Experience:

 

1988-90  Assistant Professor and Director, Urology Research Labs, Dept. of Surgery/Urology and Ben May Institute for Cancer Research, University of Chicago, Chicago, IL

1990-00  Assistant Professor (90-93), Associate Professor (93-96), Professor (96-97). Visiting Professor (97-00), Director, Tissue & Blood Bank (90-97). Departments of Human Oncology and Medicine and UW Comprehensive Cancer Center, UW-Madison, WI

1998-  Visiting Professor, Osaka University, Yokohama University, Japan; Peking University and Xiamen Univ. ,Wuhan Univ., Tianjin Medical Univ, China

1999-  Visiting Prof., Chang Gung Univ./National Taiwan Univ./Taipei Medical Univ.

1997-02  Director, Molecular Oncology Graduate Program. Univ. of Rochester, Rochester, NY

1997-  Director, George Whipple Laboratory for Cancer Research, Univ. of Rochester,

1997-  Director, Urology Research Center, University of Rochester, Rochester, NY

George Whipple Distinguished Professor, Departments of Pathology, Urology and Radiation Oncology, and The Cancer Center, University of Rochester, Rochester, NY

2000-            Founder, AndroScience Corporation. San Diego, CA.

 

Honors:

 

1988       The Ayerst Award for Outstanding Young Endocrinologist from the Endocrine Society

1989  Andrew Melon Award for Outstanding Young Faculty in USA from Andrew Melon Foundation

1990  Outstanding Young Investigator Award from Cancer Research Foundation

2003                   The Milheim Award for Excellence in Cancer Research from Milheim Foundation

1992               Tokyo Society of Medical Science and University of Tokyo Lecturer

1991-94  American Cancer Society Junior Professorship in Cancer Research

1995-97  Blowity-Ridgeway Award in Andrology from Blowity-Ridgeway Foundation

1991-97  CapCure Award (6 times) for Excellence in Prostate Cancer Research

1996  Award with Honorary Fellow from The Japan Society of Andrology (The 2nd Non-Japanese ever awarded such honor)

1998         Scholar of the Year, The highest honor from The Taiwanese Osteoporosis Association for Outstanding Contribution in Sex hormones and Osteoporosis.

1998               George Hoyt Whipple Lecture, University of Rochester, Rochester, NY

1998  Jiepimg Wu Award, for Outstanding Achievement in Urology (The highest honor for Chinese-Urology Researcher). Beijing, China.

1999  President Award for Outstanding Urology Research, The highest honor from The Urology Association of Taiwan for the Contribution in Androgen Receptor and Prostate Cancer.

1999       Davey Memorial Award for Outstanding Cancer Research, University of Rochester.

2000  President Award for Outstanding Andrology Research, The highest honor from The Taiwanese Andrology Association for the studies of Androgens and Androgen Receptor.

2001       Who’s Who in America

2001       Dr. S.T.Huang-Chan memorial Lecture/Award, University of Hong Kong.

2001-     President Award for Outstanding Andrology Research, The highest honor from The

               Chinese Andrology Association for the studies of Androgens and Androgen Receptor.

2002       Dr. Chien-Tien Hsu Memorial Lecture/Award at 2002 Annual Meeting of OBGYN      

 

Grant and Publication Review:

 

1.Member of Editorial Board, Endocrine (2000-)

2.Member of Editorial Board, The Prostate Journal(2002)

3.Member of Editorial Board, The Prostate(2003-)

4.Member of Editorial Board, Neuroimmune biology (2002)

5.Reviewer in PNAS/JBC/Mol Endo/Cancer Research and 16 other peer-reviewed journals

6.NIH Study Section: Ad Hoc & Regular Member at Biochemical Endocrinology & Other  Study Section (1995-2001)

7.NIH Study Section: Ad Hoc & Regular Member at Reproductive Endocrinology (2003)

8.VA Merit Grant Oncology Study Section (1996-2002)

9.NIH Prostate SPORE P50 Center Grant; and NIH PO1 Core Grant, NIH Research Centers in Minority Institutes Core Grant, NIH P19 Orphan Receptor Center Grant.

10.ARMY Breast and Prostate Cancer Grant Study Section (1999-)

11.Air Force TCDD Grant (reviewer) (2001)

12.Medical Research Council of Canada and Dutch Cancer Society Grant;

13.Taiwan CRC Biomedical Sciences Project and Taiwan National Science Council Grant

14.Hong Kong Earmarked Research Grant; Italian Association for Cancer Research

 

Teaching: (all in University of Rochester)

 

1.Cancer Biology (3 credit, course director)

2.Biochemistry of Steroid Hormones

3.Current Topic in Pathology and Oncology

4.Signal Transduction (2 hours lecture)

5.Toxicology (2 hours lecture)

6.Epidemiology (2 hours lecture)

7. Hormones and Cancer

7.Graduate Independent Study (current 15 Ph.D. students)

                                  

Current Research Grants: direct cost only (59% extra indirect cost for U of R)

 

2003-2006DOD-ARMY Grant, Years 1-3 ($375,000), P.I.

Knockout AR in Prostate

2003-2007NIH RO1 Grant DK61222, Years 1-4 ($900,000), P.I.

TR2 & TR4 knock-out mice

2002-2007NIH RO1 Grant DK60948, Years 1-5 ($875,000), P.I.

PTEN in prostate cancer

1993-2000NIH RO1 Grant CA103006, Years 1-3 ($600,000), P.I.

AR in prostate -bone

2002-2006NIH RO1 Grant DK60905, Years 1-4 ($700,000), P.I.

Induction of AR transactivation by DHT vs E2.

2001-2005NIH RO1 Grant DK56984, Years 1-4 ($700,000), P.I.

                                          TR4 orphan receptor in testis & prostate

2001-2004    ARMY Prostate Research Grant ($375,000), P.I.

                                          suppression of AKT signal in prostate cancer.

2002-2004ARMY Research Grant ($300,000), P.I.

PTEN in breast cancer.

1997-2022    George Whipple Professorship Endowment for 25 years

 

Previous Research Grants: direct cost only (59% extra indirect cost for U of R)

 

1995-2003NIH RO1 Grant DK47258, Year 1-8 ($1,517,400), P.I.

                     TR2 & TR3 orphan receptors in prostate cancer.

1997-2002NIH RO1 Grant CA71570, Years 1-5 ($806,592), P.I.

                     Title: AR coregulators in prostate carcinogenesis.

1993-2001NIH RO1 Grant CA55639, Years 1-9 ($569,349), P.I

                     Title: T vs DHT effects in prostate cancer.

1995-97Hollis-Eden Research Award ($60,000).

                     Title: DHEA-derivatives receptor.

1998-2000NIH-NCI Research Grant Contract ($180,000), P.I.

                     Title: ARA-A1B1 CAG repeat polymorphism

1998-2001ARMY Prostate Research Grant ($486,000), Co-P.I. (PI:Harrison.

                     Title: Androgen effects on LNCaP prostate cancer cell growth

1997-2001Rhone-Poulenc Rorer Research Award ($50,000)

Title:  AR Coregulators

1995-2000NIH RO1 Grant DK51346, Years 1-5($950,815), P.I.

AR CAG polymorphism

1998-2000    NIH Training Grant ($60,000 for Drs. Young & Yeh to study in P.I.’ lab)

1999-2002CaP CURE Research Award ($600,000), P.I.

The roles of AR in prostate

1995-1998    NIH Research Grant  CA 23563 ($465,433) Co P.I.(P.I.:Verma)

1993-1997    NIH Research Grant P30 CA 14520 ($210,000), P.I.(Tissue Bank Project) 

1992-1997    NIH Research Grant  CA 10536 ($607,331) Co P.I.(P.I.:Weindruch)

1996-1997    The Blowity-Ridgeway Foundation Award ($120,000), P.I.

1996-1997    Glaxo Research Fund ($35,000), P.I.

1992-1997    Taiwan National Science Council ($100,000 for 2 scientists studying in lab )

1990-1997    NIH Research P30 CA 14520. Co Investigator, 30% salary support

1995-1996    UW Comprehensive Cancer Center Award ($14,000), P.I.

1995-1996    UW Graduate School Research Award ($10,000), P.I.

1994-1996    Triton Research Fund ($21,400), P.I.

1994-1996    UW Medical School Merit Award ($65,000), P.I.

1994-1996      Anderson Research Fund($23,000), P.I.

1994-1995    CaP CURE Research Award ($100,000), Co P.I. (P.I.:Messing)

1994-1995    Adria Research Fund ($20,000), P.I.

1993-1994    NIH Training Grant ($40,000 for Dr. Lin to study in my lab)

1992-1994    Uehara Foundation ($20,000 for Dr. Kurada to study in my lab)

1992-1994    Shiseido Research Foundation ($35,000), P.I.

1991-1994    ACS Research Grant  BE-78 and BE-78a ($314,968), P.I.

1991-1994      University of Wisconsin Grants (4 grants for total $106,000), P.I.

1990-1993      American Cancer Society Junior Faculty Award ($90,500)

1989-1991    Cancer Research Foundation Young Investigator Award ($40,000)

1989-1991    Milheim Foundation Young Investigator Award ($20,000)

1988-1991      American Cancer Society (ACS) Research Grants ($81,415), P.I.

1988-1989    Louis Block and Coleman Foundations ($45,000), P.I.

 

Patents:

 

1. Androgen receptor and TR2 orphan receptor.

2. Androgen receptor coregulators ARA70, ARA55, ARA54, ARA24, BRCA1, Rb

3. Using differential length of androgen receptor’ and ARAs’ CAG repeat to predict prostate cancer risk in Chinese population.

4.Cross-talk between androgen receptor and other signal pathways (TGFb, Her2/Neu,MAPK, IL6/PI3K/AKT, PTEN, BRCA1, RB).

5.Using Aortic endothelial cells to screen SERMs.

6.Vitamin E as anti-prostate cancer agent

7.Androgen receptor knock out mice

8.TR2 and TR4 knock out mice

9, Antiandrogen HF avtivates MAPK pathway in prostate cancer.

10.Cucurmin analogs function as antiandrogen

 

Membership:

 

1. The Endocrine Society

2. American Society for Biochemistry and Molecular Biology

3. American Association for Cancer Research

3. American Urology Association

 

Invited Speaker:

 

I. International and National Meetings: (Total 67 since 1988)

 

1.Second International Symposium on "The Steroid/Thyroid Hormone Receptor Family

            and Gene Regulation".Stockholm, Sweden. (1988)

2.Satellite Symposium of the 8th International Congress of Endocrinology on "Steroid

            Antagonists", Kyoto, Japan. (1988)

3.Prostate Cancer National Symposia on "Molecular and Cellular Biology of Prostate

            Cancer", Prouts Neck, Maine. (1989)

4.Terra Symposia on "Androgens & Antiandrogens"  New Paltz, New York. (1991)

5.The First International Symposium on "Steroid Receptor Superfamily" UW-Madison. WI

            (1992) Symposium director.

6.First Asian & Oceanic Congress of Andrology.  Nanjing, China (1992).

7.International Symposium on Tumor Biology. Taipei, Taiwan (1994)

8.International Symposium on Sex Hormones and Antihormones. Milano, Italy (1994)

          Chairman of the Androgen Section.

9.American Urological Association Summer Research Conference. Houston, Texas (1994)

10.The American Association for Cancer Research/Taiwan Conference. Taipei, Taiwan  (1994)

11.The Second International Symposium on "Steroid Receptor Superfamily" UW-Madison. WI

            (1994) Symposium director.

12.The Second International Conference on Androgens. Long Beach, CA (1995)

13.Mary Lasker Symposium on Frontiers of Cancer Research. San Diego, CA (1995)

14.The Second Annual CaP CURE Scientific Meeting. Santa Barbara, CA (1995)

15.The Second Symposium of Severtance Institute of Andrology, Seoul, Korea (1996)

16.The Third Annual CaP CURE Scientific Meeting. Lake Tahoe, CA (1996)

17.The 10th International Congress of Endocrinology. SF, CA (1996)

18.National Prostate Cancer Coalition. Houston, TX (1996)

19.The Third International Symposium on "Steroid Receptor Superfamily" UW-Madison. WI

             (1996), Symposium director.

20.The Fourth Annual CaP CURE Scientific Meeting. Lake Tahoe, CA (1997)

21.Golden Conference. New England (1997)

22.The VIth International Congress of Andrology. Salzburg, Austria (1997), Plenary Lecture

23.Cambridge Symposium on ”Gene Transcription and Therapeutic Interaction”. Washington

             D.C. (1997)

24.The 7th SCBA International Symposium on Hormone Action, Toronto, Canada (1997)

25.International Symposium of “Molecular Basis of Sex Hormone Receptor Function-New

             Targets for Intervention” Berlin, Germany (1997)

26.The International Symposium for 50th Year Urology in Yokohama City University, Japan.

       (1997), Keynote speaker.

27.The Japan Annual Andrology Meeting. Yokohama, Japan. (1997), Keynote speaker

28.The China Andrology Meeting, Yichong, China (1997), Keynote speaker.

29.The Annual Endocrine Society Meeting, Minneapolis, (1997)

30.The Fifth Annual CaP CURE Scientific Meeting. Lake Tahoe, CA (1998)

31.The China-Japan International Urology Symposium, Shanghai, China, Keynote speaker (1998)

32.The Annual China Urology Meeting, Shanghai, China, Keynote speaker (1998)

33.Keystone Symposium on “Nuclear Receptor Gene Family” (1998)

34.The First International Chinese Urology Symposium, Shanghai, China, Keynote speaker (1998)

35.The Annual Taiwan Urology Meeting, Hualein, Taiwan, Keynote speaker (1999)

36.AACR Conference on “The Steroid Receptor Superfamily” Palm Springs, CA (1999)

37.The 8th SCBA International Symposium on Hormone Action, Hong Hong (1999)

38.The Annual Taiwanese Osteoporosis Association Meeting, Kaohsiung, Taiwan,          

             Keynote speaker (1999)

39. International Conferences on Gene Therapy and Mol. Biology & Medicine, Grete, Greece (1999)

40.The Sixth Annual CaP CURE Scientific Meeting. Lake Tahoe, CA (1999)

41.The Annual Endocrine Society Meeting, San Diego, (1999)

42.The 92nd Annual Meeting of Formosan Medical Association, Taipei, (1999)

43.Golden Conference. New England (1999)

44.North American Taiwanese Professor Association-Southern California Chapter, Irvine, CA (1999)

45.The Asia-Pacific International Urology Meeting, Beijing, China, Keynote speaker (2000)

46.17th Meeting of the International Academy of Tumor Marker Oncology, Hong Kong (2000)

47.The Second International Chinese Urology Symposium, Beijing, China, Keynote speaker (2000)

48.The Annual China Urology Meeting, Beijing, China, Keynote speaker (2000)

49.The 4th International Spinal and Muscular Atrophy Research & Clinical Meeting. St Louis (2000)

50.The Steroid Receptors and Cell Signal Pathways Symposium. Cincinnati, Ohio (2000)

51.The International Scientific Summit Conference On Current Gynecology, Taipei, Taiwan (2000)

52. The Annual Chinese Andrology Meeting, Han-Chou, China, Keynote speaker (2001)         

53. The Annual Taiwanese Andrology Meeting, Taichung, Taiwan. Keynote speaker (2001)

54.US-Taiwan Global Bio/Pharm Conference. Newark, NJ (2001)

55.Annual Meeting of Taiwanese Association of OBGYN, Taipei, Taiwan (2002)

56.The 2002 Annual Meeting of Chinese Medical Association, Taipei, Taiwan (2002)

57.The 2002 Annual Meeting of Taiwanese Urology Association, Taipei, Taiwan (2002)

58.the 3rd Conference of the Pacific Rim Society for Fertility and Sterility, Taipei, Taiwan (2002)

59.The 2002 Annual Meeting of Chinese Urology Association, Changsha, China (2002)

60.The 12th Asia-Oceania Congress of Endocrinology, Taipei, Taiwan (2002)

61.Midwest Taiwanese Summer Conference, Bowling Green, Ohio (2003)

62.Asia-Pacific Conference of Aging Male Study, Taipei, Taiwan (2003)

63.Jensen Symposium on Nuclear receptors and Endocrine Disorders, Cincinnati, Ohio (2003)

64.Taiwan Biotechnology Symposium, Chan-Wha, taiwan (2003)

65.10th SCBA International Synposium, Beijing, China.(2004)

66.Symposium on Anti-tumor Drug Discovery-from basic to clinical” Taipei, Taiwan (2003)

67.The 6th US-Taiwan neuroscience Symposium, New Orleans (2003)

 

II. University and Institute: (Total 245 since 1988)

 

1. McGill University, Department of Pediatrics, Montreal, Canada. (1988)

2. Institute of Biological Chemistry Academia Sinica, Taiwan. (1988) 

3. Baylor College of Medicine, Department of Cell Biology, Houston, Texas. (1988) 

4. Georgetown University, Department of Anatomy and Cell Biology, Washington DC. (1988) 

5. M.D. Anderson Hospital and Tumor Institute, Section of Urology, Houston, Texas. (1988)

6. National Taiwan University, Department of Biological Chemistry, Taiwan. (1988)

7. University of Chicago, Department of Madicine, Chicago, Illinois. (1988)

8. Columbia University, Department of Urology, New York, New York. (1988)

9. Mt. Sinai Medical School, Department of Urology, New York, New York. (1988)

10.Karolinska Institutet, Department of Medical Nutrition, Stockholm, Sweden. (1988)

11.Case Western Reserve University, Department of Biochemistry, Cleveland, Ohio. (1989)

12.University of Tokyo, Department of Zoology, Tokyo, Japan. (1989)

13.Chiba University, Department of Pharmacology, Chiba, Japan. (1989)

14.Osaka University, Department of Madicine, Osaka, Japan. (1989)

15.University of Chicago, Department of Surgery, Chicago, Illinois. (1989)

16.Kyushu University, Department of Madicine, Fukuoka, Japan. (1989)

17.Institute of Biomedical Sciences, Academia Sinica, Taiwan., (1989)

18.Northwestern University, Department of Pharmacology, Chicago, Illinois. (1990)

19.U. of British Columbia, Dept. of Cancer Endocrinology, Vancouver, Canada. (1990)

20.Medical College of Wisconsin, Department of Urology, Milwalkee. Wisconsin (1990)

21.National Cheng Kung University, Department of Urology, Tainan, Taiwan. (1990)

22.National Chung Heing University, Institute of Genetics, Taichung, Taiwan. (1990)

23.Veterans Hospital, Department of Urology, Taichung, Taiwan. (1990)

24.National Taiwan University, Institute of Biochemistry, Taipei, Taiwan. (1990)

25.Eli Lilly and Company, Indianapolis, Indiana. (1991)

26.Hybritech Incorporated, La Jolla, California (1991)

27.W. Alton Jones Cell Science Center, Lake Placid, New York (1991)

28.University of Wisconsin Comprehensive Cancer Center, Madison. Wisconsin (1991)

29.Merck, Sharpe & Dohme Research Laboratories, Rahway. New Jersey (1991)

30.Glaxo Inc. Research Institute, Research Triangle Park, NC. (1991)

31.Tufts University, Department of Anatomy and Cell Biology, Boston. Massachusetts (1992)

32.Ohita University, Department of Dermatology, Ohita. Japan (1992)

33.Shiseido Research Center, Yokohama. Japan (1992)

34.University of Tokyo, Depart of Dermatology, Tokyo. Japan (1992)

35.Taisho Phamaceutical Company, Ohmia. Japan (1992)

36.Chiba University, Department of Urology, Chiba. Japan (1992)

37.Tokyo Medical Society, Tokyo. Japan (1992)

38.Yokohama University, Department of Dermatology, Yokohama, Japan (1992)

39.Iwate Medical University, Department of Biochemistry, Morioka, Japan (1992)

40.Krume University, Department of Dermatology, Kurume. Japan (1992)

41.University of Wisconsin, Endocrinology Program. Madison, Wisconsin (1993)

42.Pacific Chemical Company, Seoul. Korea (1992)

43.Korea Institute of Science and Technology, Taejon. Korea (1992)

44.National Chi-Hua University, Institute of Life Science, Hsinchu. Taiwan (1992)

45.Veterans General Hospital, Taipei. Taiwan (1992)

46.Institute of Biological Chemistry, Academia Sinica, Taipei. Taiwan (1992)

47.Merck, Sharpe & Dohme Research Laboratories, West Point, PA. (1993)

48.Marion Merrell Dow Research Institute, Cincinnati, Ohio (1993)

49.University of Southern Illinois, Department of Pharmacology, Springfield, Illinois (1993)

50.University of Wisconsin, Department of Madicine. Madison, Wisconsin (1993)

51.Glaxo Inc. Research Institute, Research Triangle Park, NC. (1993)

52.La Jolla Cancer Research Foundation, San Diego, CA. (1993)

53.PharMingen, San Diego, CA. (1993)

54.University of Wisconsin, Institute on Aging. Madison, Wisconsin (1993)

55.Acracetus Inc. Middleton, Wisconsin (1994)

56.Ohio State University, Department of Biochemistry, Columbus, Ohio (1994)

57.University of Southern California, Department of Biochemistry, Los Angeles, CA (1994)

58.Harvard University, Institute on Aging, Boston, MA (1994)

59.Institute of Zoology, Chinese Academy of Sciences, China (1994)

60.State Key Lab of Reproductive Biology, Academia Sinica, China  (1994)

61.Shanghai Institute of Biochemistry, Academia Sinica, China (1994)

62.Fudan University, Department of Biology, Shanghai, China (1994)

63.Shanghai Cancer Research Center, China (1994)

64.Ther-Chiang Madical University, Department of Biochemistry, China (1994)

65.Harbor UCLA Medical Center, Department of Pathology, Torrance, CA (1994)

66.Panvera Biotech. Madison, WI (1994)

67.Memorial Sloan-Kettering Cancer Center, New York, NY (1994)

68.Yamanouchi Pharmaceutical Company, Tsukuba, Japan (1994)

69.Tokyo University of Agriculture, Department of Biochemistry, Tokyo, Japan (1994)

70.University of Wisconsin, Department of Human Oncology. Madison, WI (1994)

71.Sumitimo Chemical Company, Osaka, Japan (1994)

72.Shiseido Research Center, Yokohama. Japan (1994)

73.University of California-Los Angeles, Department of Obstetrics & Gynecology, CA (1994)

74.Institute of Biomedical Sciences, Academia Sinica, Taipei (1994)

75.National Yang-Ming Medical College, Department of Genetics, Taipei (1994)

76.U. of Texas Medical Branch at Galveston. Dept. of Pathology, Galveston, Texas (1994)

77.Case Western Reserve University, Cancer Center, Cleveland, Ohio. (1994)

78.University of Maryland, Department of Biochemistry, Baltimore, Maryland (1995)

79.Harvard University, Dana Farber Cancer Institute, Boston, MA (1995)

80.Johns Hopkins University, Department of Urology, Baltimore, Maryland (1995)

81.Uniformed Services University, Department of Surgery/Urology, Baltimore, MD (1995)

82.National Chung-Hsing University, Department of Animal Science, Taichung, Taiwan (1995)

83.National Cheng-Kung University, Department of Biochemistry, Tainan, Taiwan (1995)

84.Chung-Shan Madical College, Department of Nutritional Science, Taichung, Taiwan (1995)

85.Veterans General Hospital, Department of Surgery/Urology, Taichung. Taiwan (1995)

86.National Taiwan University, Department of Biochemistry, Taipei, Taiwan (1995)

87.Veterans General Hospital, Institute of Madical Research, Taipei. Taiwan (1995)

88.Development Center for Biotechnology, Taipei, Taiwan (1995)

89.University of California-San Francisco, Department of Phamacology, SF, CA (1995)

90.New Jersey Medical School. Department of Biochemistry, Newark, New Jewsey. (1995)

91.Tufts University, Department of Biology, Boston. Massachusetts (1995)

92.National Cancer Institute. Baltimore, Maryland (1995)

93.Albert Einstein College of Medicine, Department of Molecular Pharmacology, NY (!995)

94.New Jersey Medical School. Department of Urology, Newark, New Jewsey. (1995)

95.Mayo Clinic, Department of Biochemistry, Rochester, MN (1995)

96.University of Wisconsin, Department of Surgery/Urology. Madison, WI (1995)

97.Merck, Sharpe & Dohme Research Laboratories, Rahway. New Jersey. (1995)

98.University of Maryland, Department of Urology, Baltimore, Maryland (1995)

99.R.W. Johnson Pharmaceutical Research Institute, Ratitan, New Jersey. (1995)

100.University of Hamburg, Institute for Hormone Research, Hamburg, Germany. (1995)

101.University of Wisconsin, Department of Biomolecular Chemistry. Madison, WI (1995)

102.University of Rochester, Department of Pathology. Rochester, NY (1995)

103.Amgen Inc. Thousand Oaks, CA (1995)

104.Yokohama University, Department of Urology, Yokohama, Japan (1995)

105.Sumitimo Chemical Company, Osaka, Japan (1995)

106.Ono Pharmaceutical Co. Osaka, Japan (1995)

107.Kyushu University, Department of Third Madicine, Fukuoka, Japan. (1995)

108.University of Occupational and Environmental Health, Kokura, Japan. (1995)

109.University of Hiroshima, Department of Urology, Hiroshima, Japan. (1995)

110.National Chi-Hua University, Department of Life Science, Hsinchu. Taiwan (1995)

111.University of Minnesota, Department of Pharmacology. Minneapolis, MN (1995)

112.National Taiwan University, Institute of Microbiology, Taipei, Taiwan (1995)

113.Institute of Molecular Biology, Academia Sinica, Taipei (1995)

114.Chiba University, Department of Urology, Chiba, Japan. (1996)

115.Oregon Health Sciences University, Endocrinology, Porland, OR. (1996)

116.Osaka University, Department of Dermatology, Osaka, Japan. (1996)

117.Harvard Medical School, MGH Cancer Center, Boston, MA (1996)

118.Kochi Medical School, Department of Urology, Kochi, Japan. (1996)

119.Women's Health Research Institute, Radnor, PA. (1996)

120.Rhone-Poulenc Rorer Research Center, Collegeville, PA. (1996)

121.University of Wisconsin, Department of Medicine. Madison, WI (1996)

122.U. of British Columbia, Dept. of Cancer Endocrinology, Vancouver, Canada. (1996)

123.Harvard Medical School, Department of Dermatology, Boston, MA (1996)

124.University of Tokyo, Institute of Molecular & Cellular Biosciences, Tokyo, Japan (1996)

125.University of Washington, Department of Urology, Seattle, WA (1996)

126.Sumitomo Cnemical Company, Environmental Health Science Lab. Osaka, Japan (1996)

127.Oregon Region Primate Research Center, Beaverton, OR. (1996)

128.Saitama Medical School, Department of Biochemistry, Saitama, Japan (1996)

129.Parmingen Inc. San Diego, CA (1996)

130.National Yang-Ming University, Department of Biochemistry, Taiwan (1996)

131.University of Nebraska, Department of Biochemistry, Omaha, NB (1996)

132.University of Rochester, Department of Biochemistry, Rochester, NY (1996)

133.Institute of Biological Chemistry, Academia Sinica, Taipei (1996)

134.NYU-Mt. Sinai Medical School, Cancer Center, New York, New York. (1996)

135.University of Tokyo, Department of Urology, Tokyo, Japan (1996)

136.University of Laval, Department of Physiology-Endocrinology, Quebec, Canada (1996)

137.Ligand Pharmaceutical Co. San Diego, CA (1996)

138.Kyoto University, Department of Urology, Kyoto, Japan (1996)

139.National Taiwan University, Department of Urology, Taiwan (1996)

140.Northwestern University, Department of Medicine/Endocrinology, Chicago, Illinois. (1996)

141.UCLA, Department of Urology, LA, CA (1997)

142.Loyola University of Chicago, Department of Molecular Biology, Chicago, Illinois (1997)

143.University of Wisconsin, Department of Medicine/Endocrinology, Madison, WI (1997)

144.The Burnham Institute, San Diego, CA (1997)

145.Pfizer Central Research, Section of Molecular Sciences, Croton, CT (1997)

146.University of Rochester, Department of Pathology, Rochester, NY (1997)

147.Harbor-UCLA, Department of Medicine/Endocrinology, Torrance, CA (1997)

148.Institute of Biological Chemistry, Academia Sinica, Taipei (1997)

149.University of Wisconsin Comprehensive Cancer Center, Madison, WI (1997)

150.Yale University, Department of Pharmacology, New Haven, CT (1997)

151.Veterns General Hospital, Department of Surgery/Urology, Taipei. Taiwan (1997)

152.Harvard Medical School, Dana Faber Cancer Institute, Boston, MA (1997)

153.Sumitomo Cnemical Company, Environmental Health Science Lab. Osaka, Japan (1998)

154.Osaka University, Department of Urology, Osaka, Japan. (1998)

155.Univ. of Occupational and Environmental Health, Dept of Urology Kokura, Japan.(1998)

156.University of Hiroshima, Department of Urology, Hiroshima, Japan. (1998)

157.Kobe University, Department of Animal Science, Kobe, Japan. (1998)

158.Bristol Myles-Squibbe Pharmaceutical Co. Princeton NJ (1998)

159.National Yang-Ming University, Department of Urology, Taiwan (1998)

160.Beijing University, Institute of Urology, China (1998)

161.Rhone-Poulenc Rorer Research Center, Collegeville, PA. (1998)

162.University of Southern California, Department of Biochemistry, Los Angeles, CA (1998)

163.Merck, Sharpe & Dohme Research Laboratories, Rahway. New Jersey. (1998)

164.University of Pennsylvania, Department of Medicine/Endocrinology, PA (1998)

165.Annual Meeting of Beijing Urology Association, Beijing, China (1998)

166.Laboratoire de Biochimie B, Hopital Necker, The Fifth University of Paris. France (1998)

167.Burnhan Institute/La Jolla Cancer Center, La Jolla, CA (1998)

168.Institut des Neurosciences, The Sixth University of Paris. France (1998)

169.Schering-Plough Research Institute, Kenilworth, NJ (1998)

170.Xiamen University, Department of Biology, Xiamen, China (1998)

171.Iinst Natl Sante Res Med, The University of Paris at South. France (1998)

172.Keio University, Department of Urology, Tokyo, Japan (1999)

173.University of Rochester, Department of Medicine/Medical Oncology, Rochester, NY (1999)

174.Yokohama City University, Department of Urology, Yokohama, Japan (1999)

175.Snow Brand Milk Products Co. Res. Institute of Life Sci. Tochigi Japan (1999)

176.State University of New York at Buffalo, Department of Nutrition, Buffalo, NY (1999)

177.Shiseido Co. Research Institute, Yokohama, Japan (1999)

178.Chang Gung University, Department of Oncology/Medicine, Taipei, Taiwan (1999)

179.Indiana University Cancer Center, Indianapolis, IN (1999)

180.Kaosiuang Medical School, Department of Urology, Kaosiuang, Taiwan (1999)

181.Eli Lilly and Company, Indianapolis, Indiana. (1999)

182.Chang Gung University, Department of OB-GYN, Kaosiuang, Taiwan (1999)

183.Stanford University, Department of Medicine/Endocrinology, CA (1999)

184.National Taiwan University, Department of Urology, Taipei, Taiwan (1999)

185.UCSF, Department of Urology, SF, CA (1999)

186.National Cheng-Kung University, Department of Biochemistry, Tainan, Taiwan (1999)

187.Rhone-Poulenc Rorer Research Center, Collegeville, PA. (1999)

188.National Taiwan University, Institute of Biological Chemistry, Taipei, Taiwan (1999)

189.UC Davis Cancer Center, Sacramento, CA (1999)

190.Kyowa Hakko Kogyo Co-Pharmaceutical Research and Planning Dept., Tokyo, Japan (1999)

191.M.D. Anderson Hospital and Tumor Institute, Dept. Medical Oncology, Houston, Texas. (1999)

192.University of Mississippi, Department of Phamacology and Toxicology, Jackson, MS. (2000)

193.University of Southern California, Department of Pathology, Los Angeles, CA (2000)

194.Parmingen Inc. San Diego, CA (2000)

195.National Cancer Institute, NIH, Bethesda, MD (2000)

196.University of North Carolina, Department of Medicinal Chemistry, Chapel Hill, NC (2000)

197.Johns Hopkins University, Department of Biology, Baltimore, Maryland (2000)

198.Wayne State University, Department of Pathology. Detroit, MI (2000)

199.New York University, Department of Pathology, New York, NY (2000)

200.Beckman Research Institute, City of Hope, Duarte, CA (2000)

201.Chang Gung University, Department of OB-GYN, Kaosiuang, Taiwan (2000)

202.Connell University, Department of Medicine/Endocrinology, New York, NY (2000)

203.National Taiwan University, Department of OB-GYN, Taipei, Taiwan (2000)

204.Oregon Regional Primate Research Center, Beaverton, OR (2001)

205.UC Davis Cancer Center, Sacramento, CA (2001)

206.National Taiwan University, Department of Pathology, Taipei, Taiwan (2001)

207.Univ, of Pittsburgh, Cancer Institute. Pittsburgh. PA (2001)

208.National Taipei Medical University, Department of Medicine, Taipei, Taiwan (2001)

209.Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China (2001)

210.National Taiwan University, Biotechnology Seminar, Taipei, Taiwan (2001)

211.University of Washington, Department of Pathology, Seattle (2002)

212.National Yang Ming Medical University, Institute of Biochemistry, Taipei, Taiwan (2002)

213.Veterans General Hospital, Department of OBGYN, Taipei. Taiwan (2002)

214.UT Southwestern Medical School. Department of Urology. Dallas (2002)

215.National Taiwan University, Department of Agriculture Chemistry, Taipei, Taiwan (2002)

216.University of North Texas, Department of Biochemistry. Dallas (2002)

217.Ma-Kai Memorial Hospital, Department of OBGYN, Taipei. Taiwan (2002)

218.UT Health Center. Institute of Biotechnology. San Antonio (2002)

219.Baylor College of Medicine, Department of Molecular and Cellular Biology. Houston (2002)

220.University of California-San Diego, Dept of Reproductive Medicine. San Diego (2003)

221.Roswell Park Cancer Institute, Buffalo, NY (2003)

222.University of Chicago, Dept of Medicine/Endocrinology, Chicago (2003)

223.Taipei Medical Univ. Dept of OBGYN. Taiwan (2003)

224.University of Wisconsin Comprehensive Cancer Center, Madison (2003)

225.University of Southern California, Dept of Microbiology, Los Angeles, CA (2003)

226.Taipei Veterans General Hospital, Dept. of OBGYN, Taiwan (2003)

227.Case Western Reserve Univ. Dept of Biochemistry, Cleveland (2003)

228.Ohio State University, Dept of Medicine Chemistry, Columbus, Ohio (2003)

229.University of California-Los Angeles, Dept of OBGYN, Los Angeles, CA (2003)

230.Cleveland Clinic Foundation, Dept of Tumor Biology, Cleveland, (2003)

231.TAA at Columbus, Columbus, Ohio (2003)

232.John Hopkins University, Dept of Biochemistry and Molecular Biology, Baltimore (2003)

233.Cornell University, Dept of Urology, New York, (2003)

234.TAA at Cleveland, Cleveland, Ohio (2003)

235.NATPA at Southern California, LA (2003)

236.TAA at Cincinnati, Ohio (2003)

237.MD Anderson Cancer Center, Dept of Cancer Biology, Houston, (2004)

238.TAA at Houston, TX (2004)

239.TAA at Chicago, Ill (2004)

240.University North Carolina, Dept of Biochemistry, Chapel Hill, (2004)

241.TAA at North Carolina, Raleigh, NC (2004)

 

PUBLICATIONS

 

1.            Liao S, Hiipakka RA, Schilling K, Oberhauser AK, Chang C, and Judge SM (1981) in “Cellular dynamics of androgen receptor and protein induction in rat ventral prostate.” Prog. Clin. Biol. Res., 75A, 381-389.

 

2.            Liao S, Chang C, and Saltman AG (1983) “Androgen-receptor interaction: An overview.” Nobel symposium, Sweden, No.57, (Eriksson H, and Gustafsson JA eds.) pp. 407-418, Elsevier Science Publishing, New York.

 

3.            Liao S, Witte D, Schilling K, and Chang C (1984) “The use of a hydroxylapatite-filter steroid receptor assay method in the study of the modulation of androgen receptor interaction.” JSBMB, 20, 11-17.

 

4.            Liao S, Chang C, Witte D, Saltzman AG, and Hiipakka RA (1985) “Modulation of androgen receptor and androgen-dependent enhancement and repression of protein synthesis.” in Regulation of Androgen Action, (Bruchovsky N, Chapdelaine A, and Neumann F, eds.) pp.149-154, Congressdruck R. Bruckner, Berlin.

 

5.            Liao S, and Chang C (1985) “Cellular dynamics and control of androgen receptor activity.” in Interaction of Steroid Hormone Receptors with DNA (Sluyser M, ed.) pp.190-201, Ellis Horwood Ltd. Publishers, Chichester, England.

 

6.            Chang C, Hiipakka RA, and Liao S (1986) “Spermine-binding protein of rat ventral prostate: phosphorylation, cDNA structure, and gene expression.” Proc. Intl. Conf. Polyam. Life Sci. 99-100.

 

7.            Chang C, and Liao S (1987) “Topographic recognition of cyclic hydrocarbons and related compounds by receptors for androgens, estrogens, and glucocorticoids.” JSBMB., 27, 123-131.

 

8.            Chang C, Saltzman AG, Hiipakka RA, Huang I-Y, and Liao S (1987) “Prostatic spermine-binding protein: cloning and nucleotide sequence of cDNA, amino acid sequence, and androgenic control of mRNA level.”  J. Biol. Chem., 262, 2826-2831.

 

9.            Saltzman AG, Hiipakka RA, Chang C, and Liao S (1987) “Androgen repression of the production of a 29 kilodalton protein and its mRNA in the rat ventral prostate.”  J. Biol. Chem., 262, 1,432-437.

 

10.        Chang C, Saltzman AG, Sorensen NS, Hiipakka RA, and Liao S (1987) “Identification of glutathione S-transferase Yb1 mRNA as the androgen-repressed mRNA by cDNA cloning and sequence analysis.”  J. Biol. Chem., 262, 11901-11903.

 

11.        Chang C, Kokontis J, Chang C-T, and Liao S (1987) “Cloning and sequence analysis of the rat ventral prostate glucocorticoid receptor cDNA.” Nucleic Acids Res., 22, 9603.

 

12.        Liao S, Chang C, Sorensen NS, Chang C-T, and Hiipakka RA (1987) “Modulation of androgen receptor activity and the effect of androgens on gene expression for specific proteins.” in Hormonal Therapy of Prostatic Disease: Basic and Clinical Aspects (Motta, M., and Serio, M. eds) pp. 48-62, Medicom Europe, The Netherlands.

 

13.        Anderegg RJ, Carr SA, Huang I-Y, Hiipakka RA, Chang C, and Liao S (1988) “Correction of the cDNA-derived protein sequence of prostatic spermine binding protein: Pivotal role of tandem mass spectrometry in sequence analysis.” Biochemistry, 27, 4214-4221.

 

14.        Chang C, and Liao S (1988) “Gene expression and structure analysis of cDNA's for androgen-sensitive proteins and different forms of steroid-receptors.” Progress in Cancer Research and Therapy. 35, 43-48.

 

15.        Chang C, Kokontis J, and Liao S (1988) “Molecular cloning of human and rat complementary DNA encoding androgen receptors.”  Science, 240, 324-326.

 

16.        Chang C, Kokontis J, and Liao S (1988) “Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors.” Proc. Natl. Acad. Sci., 85, 7211-7215.

 

17.        Chang C, and Kokontis J (1988) “Identification of a new member of steroid receptor superfamily by cloning and sequence analysis.” BBRC, 155, 971-977.

 

18.        Liao S, Chang C, Kokontis J, Popovich T, and Hiipakka RA (1989) “Structure and intranuclear dynamics of androgen receptors.” in The Steroid/Thyroid Hormone Receptor Family and Gene Regulation. (Gustafsson, JA., Eriksson, H. and Carlstedt-Duke, J. eds). 83-92, Congressdruck R. Bruckner, Berlin, Burkhauser Verlag Basel.

 

19.        Buttyan R, Olsson CA, Pintar J, Chang C, Bandyk M, Ng P-Y, and Sawczuk SI (1989) “Induction of the TRPM-2 gene in cells undergoing programmed death.” MCB. 9, 3473-3481.

 

20.        Chang C, Whelan CT, Popovich TC, Kokontis J, and Liao S (1989) “Fusion proteins containing androgen receptor sequences and their use in the production of poly- and monoclonal anti-androgen receptor antibodies.” Endocrinology, 125, 1097-1099.

 

21.        Chang C, Chodak G, Sarsac E, Takeda H, and Liao S (1989) “Prostate androgen receptor: immunohistological localization and mRNA characterization.” JSBMB. 34, 311-313.

 

22.        Chang C, Lau L, Liao S, and Kokontis J (1989) “Characterization of  new members of steroid receptor superfamily.” in The Steroid/Thyroid Hormone Receptor Family and Gene Regulation. (Gustafsson JA, Eriksson H, and Carlstedt-Duke J eds.) 183-195, Congressdruck R. Bruckner, Berlin, Burkhauser Verlag Basel.

 

23.        Chang C Kokontis J, Acakpo-Satchivi L, Liao S, Takeda H, and Chang Y (1989) “Molecular cloning of new human TR2 receptors: A class of steroid receptor with multiple ligand-binding domains.” BBRC.165, 735-741.

 

24.        Chang C, Kokontis J, Liao S, and Chang Y (1989) “Isolation and characterization of human TR3 receptor: A member of steroid receptor superfamily.” JSBMB. 34, 391-395.

 

25.        Chang C, Kokontis J, Swift S, and Liao S (1990) “Molecular cloning and structural analysis of complementary DNA of human and rat androgen receptors.” Molecular Endocrinology and Steroid Hormone Action,  53-63.

 

26.        Simerly RB, Chang C, Muramatsu M, and Swanson LW (1990) “The distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: An in situ hybridization study.” Journal of Comparative Neurology, 294, 76-95.

 

27.        Sai T, Seino S, Chang C, Trifiro M, Pinsky L, Mhatre A, Kaufman, M, Lambert B, Trapman J, Brinkmann AO, Rosenfield RL, and Liao S (1990) “An exonic point mutation of the androgen receptor gene in a family with complete androgen insensitivity.” American Journal of Human Genetics, 46, 1095-1100.

 

28.        West NB, Chang C, Liao S, and Brenner RM (1990) “Localization and regulation of estrogen, progestin and androgen receptors in the seminal vesicle of the rhesus monkey.” JSBMB, 37. 11-21.

 

29.        Imperato-McGinley J, Ip NY, Gautier T, Neuweiler J, Gruenspan H, Liao S, Chang C, and Balazs I (1990) “DNA linkage analysis and studies of the androgen receptor gene in a large kindred with complete androgen insensitivity.” American Journal of Medical Genetics, 36, 104-108.

 

30.        Masai M, Sumiya H, Akimoto S, Yatani R, Chang C, Liao S, and Shimazaki J (1990) “Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates.” The Prostate, 17, 293-300.

 

31.        Kranc DM, Chodak GW, and Chang C (1990) “Androgen receptor staining in heterogeneous samples of normal, hyperplastic, and neoplastic human prostate.” Surgical Forum,41, 687-689.

 

32.        Takeda H, Chodak GW, Mutchnik SE, Nakamoto T, and Chang C (1990) “Immunohistochemical localization of androgen receptors with mono-and polyclonal antibodies to androgen receptor.” Journal of Endocrinology, 126, 17-27.

 

33.        Matusik RJ, Cattini PA, Leco KJ, Sheppard PC, Nickel BE, Neubauer BL, Davie JR, Chang C, Liao S, Matuo Y, and McKeehan WL (1991) “Regulation of gene expression in the prostate.” in Molecular and Cellular Biology of Prostate Cancer, 299-314, Plenum, New York.

 

34.        Takeda H, Nakamoto T, Kokontis J, Chodak GW, and Chang C.(1991) “Autoregulation of androgen receptor expression in rodent prostate: Immunohistochemical and in situ hybridization analysis.” BBRC, 177, 488-496.

 

35.        Kokontis J, Nakamoto T, and Chang C (1991) “Structural analysis and gene expression of TR2 receptor and TR3 receptor.” Molecular and Cellular Biology of Prostate Cancer, 229-234. Plenum, New York.

 

36.        Takeda H, and Chang C (1991) “Immunohistochemical and in situ hybridization analysis of androgen receptor expression during the development of mouse prostate gland.” Journal of Endocrinology, 129, 83-91.

 

37.        Trifiro M, Gottlieb B, Pinsky L, Kaufman M, Prior L, Belsham DD, Wrogemann K, Brown CJ, Willard HF, Trapman J, Brinkmann AO, Chang C, Liao S, Sergovich F, and Jung J (1991) “The 56/58 kDa androgen-binding protein in male genital skin fibroblasts with a deleted androgen receptor gene.” Molecular and Cellular Endocrinology,75, 37-47.

 

38.        Chang C, Takeda H, and Kokontis J (1991) “cDNA cloning, antibody production and immunohistochemical localization of the androgen receptor.” Molecular and Cellular Biology of Prostate Cancer,  235-241, Plenum, New York.

 

39.        Mestayer C, Gabou L, Portois MC, Boucekkine C, Chang C, and Mowszowicz I.(1991) “Expression du gene durpecepteur des androgenes chez des sujets normaux et des patients presentant une insensibilite complete aux androgenes.” Annales d'Endocrinologie 52, 431-434.

 

40.        Sanborn BM, Caston LA, Chang C, Liao S, Speller R, Porter LD, and Ku CY (1991) “Regulation of androgen receptor mRNA in rat sertoli and peritubular cells.” Biology Reproduction, 45, 634-641.

 

41.        Kokontis J, Liao S, and Chang C.(1991) “Transcriptional activation by TR3 receptor, a member of steroid receptor superfamily.”  Receptor, 1, 261-270.

 

42.        Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, and Chang C (1992) “Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic, and neoplastic human prostate.”  Journal of Urology, 147, 798-803.

 

43.        Nakamoto T, Chang C, Li A, and Chodak GW (1992) “Basic fibroblast growth factors in human prostate cancer cells.”  Cancer Research, 52, 571-577.

 

44.        Prior L, Bordet S,Trifiro MA, Mhatre A, Kaufman M, Pinsky L, Wrogeman K, Belsham DD, Pereira F, Greenberg C, Trapman J, Brinkmann AO, Chang C, and Liao S (1992) “Replacement of arginine 773 by cysteine or histidine in the human androgen receptor causes complete androgen insensitivity with different receptor phenotypes.” American Journal of Human Genetics, 51, 143-155.

 

45.        Gipp JJ, Chang C, and Mulcahy RT. (1992) “Cloning and nucleotide sequence of a full-length cDNA for human liver g glutamylcysteine synthetase.” BBRC, 185, 29-35.

 

46.        Leav I, Kwan PW-L, Merk FB, Chang C, and Ho S-M. (1992) “Immunohistochemical and in situ hybridization studies of androgen receptor expression in a transplantable androgen-independent prostate carcinoma cell line of AIT noble rats.” Laboratory Investigation, 67, 788-795.

 

47.        Jiang S-Y, Wolf DM, Yingling JM, Chang C, and Jordan VC. (1992) “An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.” Molecular and Cellular Endocrinology, 90, 77-86.

 

48.        Chang C, Wang C, Deluca HF, Ross TK, and Shih CC-Y (1992) “Characterization  of an human androgen receptor overexpressed in the baculovirus system.” Proc. Natl. Acad. Sci., 89, 5946-5950.

 

49.        Kaku A, Chang C, Tamura T, Okamoto T, and Yoshimura Y. (1993) “Immunolocalization of androgen receptor in the cloacal gland of male Japanese quail (Coturnis coturnix japonica).” Japanese Poultry Science, 30, 413-418.

 

50.        Rennie PB, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoeck R, Hamel A, Bock ME, MacDonald BS, Nickel BE, Chang C, Liao S, Cattini PA, and Matusik RJ (1993) “Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene.” Mol. Endocrinology, 7, 23-36.

 

51.        Mowszowicz I, Lee H-J, Chen H-T, Mestayer C, Portois M-C, Carbrol S, Mauvais-Jarvis P, and Chang C (1993) “A point mutation in the second zinc-finger of the DNA-binding domain of the androgen receptor gene causes complete androgen insensitivity in two siblings with receptor-positive androgen resistance.” Mol. Endocrinology. 7, 861-869.

 

52.        Lee H-J, Kokontis J, Wang K-C, and Chang C (1993) “The use of a DNA-binding domain replacement method for the detection of a potential TR3 orphan receptor response element in the mouse mammary tumor virus long terminal repeat.” BBRC. 194, 97-103.

 

53.        Yoshimura Y, Chang C, Okamoto T, and Tamura T (1993) “Immunolocalization of androgen receptor in the small, preovulatory and postovulatory follicles of laying hens.” General and Comparative Endocrinology, 91, 81-89.

 

54.        Mowszowicz I, Lee H-J, Portois M-C, Kuttenn F, and Chang C (1993) “Complete androgen insensitivity due to a single base substitution in exon 8 of the steroid-binding domain of the androgen receptor.” Endocrine, 1, 203-209.

 

55.        Zhang Y-L, Wang C, Wilding G, and Chang C (1993) “Identification of an androgen-induced C3-P4 DNA binding protein in the cytosol of rat ventral prostate.” BBRC. 195, 710-716.

 

56.        Chang C, Saltzman AG, Lee H, Uemura H, Su C, Chodak GW, Nakamoto T, LeBeau M, Espinosa R, Davis E, Lemons R, Sivak L, and Shih C (1993) “Genomic structure, chromosomal localization and expression of an inducible TR3 orphan receptor: A member of the steroid receptor superfamily.” Endocrine, 1, 541-549.

 

57.        Mizuno Y, Hosoi T, Inoue S, Ikegami A, Kaneki M, Akedo Y, Nakamura T, Ouchi Y, Chang C, and Orimo H (1994) “Immunocytochemical identification of androgen receptors in mouse osteoclast-like multinucleated cells.”  Calcified Tissue International 54, 325-326.

 

58.        Mizokami A, Yeh S, and Chang C (1994) “Identification of 3', 5' cyclic adenosine monophosphate response element and other cis-acting elements in human androgen receptor gene promoter.” Mol. Endocrinology 8, 77-88.

 

59.        Young W-J, Roecker EB, Weindruch R, and Chang C (1994) “Quantitation of androgen receptor mRNA by competitive reverse transcription-polymerase chain reaction.” Endocrine 2, 321-329.

 

60.        Mizokami A, and Chang C (1994) “Induction of translation by 5'-untranslated region of human androgen receptor mRNA.” J. Biol. Chem. 269, 25655-25659.

 

61.        Lustig RH, Hua P, Smith LS, Wang C, and Chang C (1994) “An in vitro model for the effects of androgen on neurons employing androgen receptor-transfected PC12 cells.” Mol. Cel. Neuro Sciences. 5, 587-596.

 

62.        Chang C, Da Silva SL, Ideta R, Lee Y-F, Yeh S, and Burbach JPH (1994) “Human and rat TR4 orphan receptors specify a subclass of the steroid receptor superfamily.” PNAS 91, 6040-6044.

 

63.        Pugh TD, Chang C, Uemura H and Weindruch R (1994) “Prostatic localization of spontaneous early invasive carcinoma in Lobund-Wistar rats.” Cancer Research 54, 5766-5770.

 

64.        Joubert Y, Tobin C, Lebart MC and Chang C (1994) “Ultrastructural localization of androgen receptors in levator ani muscle in the rat.” Proc. Intl. Conf. Elec. Microscopy 13, 325-326.

 

65.        Ideta R, Yeh S, Lee YF, Adachi K, Takeda H, Su C, Saltzman A and Chang C (1995) “Gene expression of the androgen repressed rat TR2 orphan receptor: a member of steroid receptor superfamily.” Endocrine, 3, 277-283.

 

66.        Da Silva SL, Van Horssen AM, Chang C, and Burbach JPH (1995) “Expression of nuclear hormone receptors in the rat supraoptic nucleus.” Endocrinology, 136, 2276-2283.

 

67.        Garcias-Arenas R, Lin F-F, Lin D-L, Jin L-P, Shih C-Y, Chang C, and LinM-F “The expression of prostatic acid phosphatase is transcriptionally regulated in human prostate carcinoma cells.” Mol. and Cel. Endo. 111, 29-37.

 

68.        Chang C, Saltzman A, Yeh S, Young W-J, Keller E, Lee H-J, Wang C, and Mizokami A (1995) “Androgen receptors: an overview.” Critical Reviews in Eukaryotic Gene Expression, 5(2), 97-125.

 

69.        Uemura H, Mizokami A, and Chang C (1995) “Identification of a new enhancer in the promoter region of human TR3 orphan receptor gene: a member of steroid receptor superfamily.” J. Biol. Chem. 270, 5427-5433.

 

70.        Lee H-J, and Chang C (1995) “Identification of human TR2 orphan receptor response element in the transcriptional initiation site of the Simian Virus 40 major late promoter.” J. Biol. Chem. 270, 5434-5440.

 

71.        Lin T-M, Young W-J, and Chang C (1995) “Multiple functions of the TR2-11 orphan receptor in modulating activation of two key cis-acting elements involved in the retinoic acid signal transduction system.” J. Biol. Chem. 270, 30121-30128.

 

72.        Lee H, Lee Y, Burbach P, and Chang C (1995) “Suppression of gene expression on the Simian Virus 40 major late promoter by human TR4 orphan receptor: a member of steroid receptor superfamily.” J. Biol. Chem. 270, 30129-30133.

 

73.        Yuan Z, Zhang Y, Chang C and Zhang YL (1995) “Differential regulation of glutathione S-transferase -Yb1 mRNA levels in rat prostate, liver, and brain by androgen.” Cell Research, 55, 235-242.

 

74.        Chang C, Lin T-M, Hsiao P, Su C, Riebe J, and Lin D-L (1996) “Androgen-responsive genes.” In: Pharmacology, Biology and Clinical Application of Androgens. (Basin C, and Swarlorf G eds). pp. 65-71, Wiley-Liss, Inc.

 

75.         Su C-Y, Chang C, and Lai C-C (1996) “Induction of heat shock proteins by exercise.” in Pharmacology in Exercise and Sports. (Somani SM ed), pp. 147-167, CRC Press, London.

 

76.         Lin T, Lustig RH, and Chang C (1996) “The role of androgens-androgen receptor in immune system activity.” in: The Physiology of Immunity (Marsh JA and Kendall MD eds) pp. 263-276, CRC Press, Boca Raton FL.

 

77.        Keller ET, Ershler WB, and Chang C (1996) “The androgen receptor: a mediator of diverse responses.” Frontiers in Bioscience 1: d59-71.

 

78.        Yeh S, and Chang C (1996) “Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.”  Proc. Natl. Acad. Sci. 93: 5517-5521.

 

79.        Lee H-J, Young W-J, Shih CC-Y and Chang C (1996) “Suppression of the human erythropoietin expression gene by the TR2 orphan receptor: a member of steroid receptor superfamily.” J. Biol. Chem. 271, 10405-10412.

 

80.        Lin D-L, and Chang C (1996) “P53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of steroid receptor superfamily.” J. Biol. Chem. 271, 14649-14652.

 

81.         Lee H-J, Mowszowicz I, and Chang C (1996) “The first detection of complete androgen insensitivity with no mutation in the coding sequence of the androgen receptor gene.” Frontiers in Bioscience 1: a34-38.

 

82.        Keller ET, Chang C, and Ershler WB (1996) “Inhibition of NFkB activity through maintenance of IkBa  levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter.” J. Biol. Chem. 271, No.9055, 26267-26275.

 

83.        Yeh S, Miyamoto H, and Chang C (1997) “Hydroxyflutamide may not always be a pure antiandrogen.” The Lancet 349, 852.

 

84.        Obana N, Chang C, and Uno H (1997) “Inhibition of hair growth by testosterone in the presence of dermal papilla cells from the frontal bald scalp of the postpubertal stumptailed macaque.” Endocrinology, 138, 356-361.

 

85.        Miyamoto H, Yeh S, Kinoshita H, Fujimoto N, Nishimura K, Inui S, Mizokami A, Uemura H, and Chang C (1997) “Androgen receptor and androgen receptor cofactors in prostate.” Proc. Jap. Nat. Conf. Andrology, 1-4.

 

86.        Yeh S, and Chang C (1997) “The effect of androgens and 17b-estradiol on the androgen receptor transcriptional activity in the presence of the androgen receptor coactivator ARA70 in human prostate DU145 cells.” from: Current Advances in Andrology (Waites G. Frick J and Baker G ed) pp. 17-22 Monduzzi Editore Italy.

 

87.        Young W-J, Smith SM, and Chang C (1997) “Induction of the intronic enhancer of the human ciliary neurotrophic factor receptor (CNTFR) a gene by the TR4 orphan receptor.” J. Biol. Chem. 272, 3109-3116.

 

88.        Lee YF, Pan H-J, Burbach JPH, Morkin E, and Chang C (1997) “Identification of direct-repeat 4 as a positive regulatory element for the human TR4 orphan receptor: a modulator for the thyroid hormone target genes.” J. Biol. Chem. 272, 12215-12220.

 

89.        Yeh S, and Chang C (1997) “ARA70, Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.” Worldwide Documents in Prostatic Cancer & BPH 5, 2-3.

 

90.        Lin T-M, and Chang C (1997) “Cloning and Characterization of TDD5, an androgen target gene that is differentially repressed by testosterone and dihydrotestosterone.” Proc. Natl. Acad. Sci. 94, 4988-4993.

 

91.        Wiren KM, Zhang X, Chang C, Keenan E, and Orwoll ES (1997) “Transcriptional up-regulation of the human androgen receptor by androgen in bone cells.” Endocrinology 138, 2291-2300.

 

92.        Magi-Galluzzi C, Xu X, Hlarty L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C, and Loda M (1997) “Heterogeneity of androgen receptor content in advanced prostate cancer.” Modern Pathology, 10, 839-845.

 

93.        Chang C, and Lee H (1997) “Identification of the human aldolase A gene as the first induced target for the human TR2 orphan receptor: a member of the steroid hormone receptor superfamily.” Biomed. Biophysic. Res. Commun. 235, 205-211.

 

94.        Schirar A, Chang C, and Rousseau JP (1997) “Localization of androgen receptor in nitric oxide synthase- and vasoactive intestinal peptide-containing neurons of the major pelvic ganglion innervating the rat penis.” Journal of Neuroendocrinology 9, 141-150.

 

95.        Lin M-F, Meng T-C, Roa PS, Chang C, Schonthal AH, and Lin F-F (1998) “Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines.” J. Biol. Chem. 273, 5939-5947.

 

96.        Uemura H, and Chang C (1998) “Antisense TR3 orphan receptor can increase prostate cancer cell viability with Etoposide treatment.” Endocrinology 139, 2329-2334.

 

97.        Lin D-L Wu S-Q, and Chang C (1998) “The genomic structure and chromosomal location of the human TR2 orphan receptor: a member of steroid receptor superfamily.” Endocrine 8, 123-134.

 

98.        Lee Y-F, Young W-J, Burbach JPH, and Chang C (1998) “Negative feedback control of the retinoid-retinoic acid/retinoid X receptor pathway by the human TR4 orphan receptor: a member of steroid receptor superfamily.” J. Biol. Chem.  273, 13437-13443.

 

99.        Yeh S, Miyamoto H, Shima H, and Chang C (1998) “From estrogen to androgen receptor: a new pathway for sex hormone in prostate.”  Proc. Natl. Acad. Sci. 95, 5527-5532.

 

100.    Miyamoto H, Yeh S, Wilding G, and Chang C (1998) “Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.” Proc. Natl. Acad. Sci. 95, 7379-7384.

 

101.    Huang S-B, Burbach JPH, and Chang C, (1998) "TR4 orphan receptor crosstalks to chicken ovalbumin upstream protein-transcription factor and thyroid hormone receptor to induce the transcriptional activity of the human immunodeficiency virus type-1 long terminal repeat." Endocrine, 8, 169-175.

 

102.    Su C, Chong K, Dillmann W, Chang C, Owen O, and Lai C (1998) “Constitutive and inducible hsps70s are involved in oxidative resistance evoked by heat shock or ethanol.” J. Mol. Cell Cardiology 30, 587-598.

 

103.    Chong K-Y, Lai C-C, Lilly S, Chang C, and Su C-Y (1998) “Stable overexpression of the constitutive form of heat shock protein 70 confers oxidative protection.” J. Mol. Cell Cardiol. 30, 599-608.

 

104.    Miyamoto H, Yeh S, Huang S-B, Fugimoto N, Hsiao P, Ting H, Inui S, Nishimura K, Wang C, Uemura H, Kang H, and Chang C (1998) “The Androgen Receptor Coregulator ARA70.” in Molecular Basis of Sex Hormone Receptor Function (Gronemeyer H, Fugymann U and Parczyk ed) pp. 43-51, Springer, Berlin.

 

105.    Young W-J, Lee Y-F, Smith SM, and Chang C (1998) “A bi-directional regulation between the TR2/TR4 orphan receptors (TR2/TR4) and the ciliary neurotrophic factor (CNFT) signaling pathway.” J. Biol. Chem. 273, 20877-20885.

 

106.    Chen X, Zachar V, Chang C, Ebbesen P, and Liu X (1998) “Differential expression of Nur77 family members in human T-lymphotropic virus type 1-infected cells: transactivation of the TR3/Nur77 gene by Tax protein.”  J. of Virology 72, 6902-6906.

 

107.    Young W-J, and Chang C (1998) “Ontogeny and autoregulation of androgen receptor mRNA expression in the nervous system.” Endocrine  9, 79-88.

 

108.    Chang C, and Pan, H-J (1998) “Thyroid hormone direct repeat 4 response element is a positive regulatory element for the human TR2 orphan receptor, a member of the steroid receptor superfamily.” MCB. 189, 195-200.

 

109.    Mu X. Young W-J, Liu Y-X, Uemura H, and Chang C (1998) “Induction of an intronic enhancer of the human ciliary neurotrophic factor receptor (CNTFRa) gene by the TR3 orphan receptor.” Endocrine 9, 27-32.

 

110.     Pan H-J, Wilding G, Uno H, Inui S, Goldsmith L, Messing E, and Chang C (1998) “Evaluation of RU58841 as an antiandrogen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of Stumptailed Macaques.” Endocrine 9, 39-43.

 

111.    Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, and Chang C (1998) “Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells.” BBRC. 248, 361-367.

 

112.    Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, and Nassif N (1998) “Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.” Cancer Research 58, 5310-5314.

 

113.    Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, and Castagna G (1998) “Androgen receptors in ovarian tumors: correlation with Oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study.” J. Exp. Clin. Cancer Res. 17.2, 231-237.

 

114.    Miyamoto H, Yeh S, Lardy H, Messing E, and Chang C (1998) “Delta5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.” Proc. Natl. Acad. Sci.19, 11083-11088.

 

115.    Cardillo MR, Petrangeli E, Ravenna L, Salvatori L, Chang C, DiSilverio F (1998) “Immunohistochemical quantification and determination of Cathepsin D in prostatic neoplasia: correlation with steroid.” Applied Immunohistochemistry 6(3), 133-139.

 

116.    Mu XM, Liu YX and Chang C (1998) “Mechanism of the interaction between orphan receptor TR3 and cis-acting element in CNTFRa gene.” Chinese J. Biochemistry and Molecular Biology 14, 484-492.

 

117.    Kang H-Y, Yeh S, Fujimoto N, and Chang C (1999) “Cloning and characterization of human prostate coactivator, ARA54, a novel protein that associates with the androgen receptor.” J. Biol. Chem. 274, 8570-8576.

 

118.    Yeh S, Chang H, Miyamoto H, Takatera H, Rahman M, Kang H, Thin T, Lin D, and Chang C (1999) “Differential induction of androgen receptor transcriptional activity by selective androgen receptor coactivators.” Keio J. of Medicine 48, 87-92.

 

119.    Wang C, Young W-J, and Chang C (1999) “Androgen effects on the solubility and conformational change of androgen receptor in baculovirus expression system.” MCB. 195, 19-23.

 

120.    Inui, S, Lee Y-F, Haake AR, Goldsmith LA, and Chang C (1999) “Induction of TR4 orphan receptor by retinoic acid in human HaCaT keratinocytes.” Journal of Investigative Dermatology 112, 426-431.

 

121.    Heinlein CA, Ting H-J, Yeh S, and Chang C (1999) “Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma.” J. Biol. Chem. 274, 16147-16152.

 

122.    Yeh S, Lin H-K, Kang H-Y, Thin TH, Lin M-F, and Chang C (1999) “From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.” Proc. Natl. Acad. Sci. 96, 5458-5463.

 

123.    Lee H-J, Lee Y-F, and Chang C (1999) “Identification of the histamine H1 receptor gene as a differentially repressed target of the human TR2 orphan receptor.”  MCB. 194, 199-207.

 

124.    Lee Y-F. Young W-J, Lin W-J, Shyr C-R, and Chang C (1999) “Differential regulation of direct repeat 3 Vitamin D3 and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor.”  J. Biol. Chem. 274, 16198-16205.

 

125.    Hsiao P and Chang C (1999) “Isolation and characterization of ARA160 as an androgen receptor N-terminal associated coactivator in human prostate cells.” J. Biol. Chem. 274, 22373-22379.

 

126.    Hsiao P, Lin D, Nakao K, and Chang C (1999) “The linkage of the Kennedy’s neuron disease to ARA24, the first identified androgen receptor poly-glutamine region-associated coactivator.” J. Biol. Chem. 274, 20229-20234.

 

127.    Yang C, Yeh S, Leskov K, Odegaard E, Hsu H, Chang C Kinsella T, Cheb D, and Boothman D (1999) “Isolation of Ku70-binding proteins (KUBs).” Nucleic Acid Res. 27, 2165-2174.

 

128.    Fujimoto N, Yeh S, Kang H-Y, Inui S, Chang H-C, Mizokami A, and Chang C (1999) “Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate.” J. Biol. Chem. 274, 8316-8321.

 

129.    Lee Y, Shyr C, Thin T, and Chang C (1999) “Convergence of two repressors through heterodimer formation of androgen receptor and TR4 orphan nuclear receptor: a new signaling pathway in the steroid receptor superfamily.” Proc. Natl. Acad. Sci. 96, 14724-14729.

 

130.    Shih C, Young W, Wang C, Jin L, Ji X, Guan Q, Wang M, and Chang C (1999) “Monoclonal anti-androgen receptor antibodies: production, characterization, and potential diagnostic applications.” MCB. 201, 131-140.

 

131.    Kameoka Sei, Leavitt P, Chang C, and Kuo SM (1999) “Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary flavonoids.” Cancer Letters 146, 161-167.

 

132.    Yeh S, Kang H, Miyamoto H, Nishimura K, Chang H, Fujimoto N, Ting H, Mizokami A, Huang K, and Chang C (1999) “Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate DU145 cells.” Endocrine 11, 195-202.

 

133.    Chang HC, Miyamoto H, Yeh S, Lardy H, and Chang C (1999) “Suppression of Delta5-Androstenediol-induced AR transactivation by selective steroids in human prostate cancer cells.” Proc. Natl. Acad. Sci. 96, 11173-11177.

 

134.    Pan H, Uno H, Obana N, and Chang C (1999) “The roles of testosterone in the growth of keratinocytes through bald frontal dermal papilla cells.” Endocrine 11, 321-327.

 

135.    Liu X, Chen X, Zachar V, Chang C, and Ebbesen P (1999) “Transcriptional activation of human TR3/nur77 gene expression by human T-lymphotropic Virus type I Tax protein through two AP-1-like elements.” J. of General Virology 80, 3073-3081.

 

136.    Miyamoto H, and Chang C (2000) “Antiandrogens fail to block completely the androstenedione-induced mutated androgen receptor transactivation in human prostate cancer cells.” International J. Urology 7, 32-34.

 

137.    Inui S, Itami S, Pan H, and Chang C (2000) “Lack of androgen receptor transcriptional activity in human keratinocytes.” J. Dermatological Science 23, 87-92.

 

138.    Nishimura K, Sampson E, Yan S, Kim E, Wang X, Uemura H, Wang C, Fujimoto N, Kang H, Yeh S, and Chang C (2000) “Yeast two-hybrid screening of associated proteins and characterization of mutant androgen receptors.” 329-343 in Yeast Hybrid Technologies (Zhu L and Hannon G ed). Eaton Publishing.

 

139.     Lin D, and Chang C (2000) “Identification and characterization of an essential cis-acting element (TR2-PACE) in the 5' promoter of human TR2 orphan nuclear receptor gene.” Endocrine 12, 89-97.

 

140.    Hsiao P, Thin T, Lin D, and Chang C (2000) “Differential regulation of testosterone vs 5a-dihydrotestosterone by selective androgen response elements.” MCB. 206, 169-175.

 

141.    Wang C, Young W, and Chang C (2000) “Isolation and characterization of androgen receptor mutants with divergent transcriptional activity in response to hydroxyflutamide.” Endocrine 12, 69-76.

 

142.    Lee K, Duo J, Hsiao P, and Chang C (2000) “From androgen receptor to general transcription factor TFIIH: Identification of cdk Activating Kinase as an AR N-terminal associated coactivator.” J. Biol. Chem. 275, 9308-9313.

 

143.     Hsing A, Gao Y, Wu G, Chen Y, Deng j, Sesterhenn I, Mostofi F, and Chang C (2000) “Polymorphic CAG/CAA repeat length in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China.” Cancer Research 60, 5111-5116.

 

144.    Yeh S, Hu Y, Rahman M, Lin H, Ting H, Kang H, and Chang C (2000) “Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.” Proc. Natl. Acad. Sci. 97, 11256-11261.

 

145.    Yeh S, Sampson E, Lee DK, Kim E, Hsu C, Chen Y, Chang HC, Altuwaijri S, Huang K, and Chang C (2000) “Functional analysis of N-terminal and Ligand-binding domain of androgen receptor coactivators in prostate cancer.” J. Formosan Medical Association 99, 885-894.

 

146.    Schaick H, Rosmalen J, Silva S, Chang C, and Burbach P (2000) “Expression of the orphan receptor TR4 during brain development of the rat.” Mol. Brain Res. 77, 104-110.

 

147.    Mu X, Liu Y, Collins L, Kim E, and Chang C (2000) “The p53/Rb-mediated repression of testicular orphan receptor-2 in the rhesus monkey with crytorchidism.” J. Biol. Chem. 275, 23877-23883.

 

148.    Kinoshita H, Shi Y, Sandefur C, Meisner L, Chang C, Choon A, Reznikoff C, Bova S, Friedel A, and Jarrard D (2000) “Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer.” Cancer Research 60, 3623-3630.

 

149.    Kang HY, Lin HK, Hu YC, Yeh  S, Huang KE, and Chang C  (2001) “From TGF-b signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells.” Proc. Natl. Acad. Sci. 98, 3018-3023.

 

150.    Lee DK, Duan HO, and Chang C (2001) “Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation.” J. Biol. Chem 276, 9978-9984.

 

151.    Lin H, Yeh S, Kang H, and Chang C (2001) “Akt suppresses androgen-induced apoptosis by phosphorylatiing and inhibiting androgen receptor.” Proc. Natl. Acad. Sci. 98, 7200-7205.

 

152.    Heinlein CA, and Chang C (2001) “The role of chaperones in the nuclear translocation and transactivation of steroid receptors.” Endocrine 14, 143-149.

 

153.    Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Messing E, Chang C, and Wu D (2001) “Localization of androgen receptor expression in human bone marrow.” J. Pathology 193, 361-366.

 

154.    Si M, AI-Sharafi B, Lai C, Khardori R, Chang C, and Su C. (2001) “Gender difference in cytoprotection induced by estrogen on female and male bovine aortic endothelial cells.” Endocrine 15, 255-262.

 

155.    Sampson E, Yeh S, Chang H, Tsai M, Wang X, Ting H-J, and Chang C (2001) “Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.” J. Biological Regulation & Homeostatic Agents 15, 123-129.

 

156.    Collins L, Lin D, Mu X, and Chang C (2001) “Feedback regulation between orphan nuclear receptor TR2 and human papilloma virus type 16.” J. Biol. Chem.  276, 27316-27321.

 

157.    Lee HJ, Lee YF, and Chang C (2001) “TR4 orphan receptor represses the human steroid 21-hydroxylase gene expression through the monomeric AGGTCA motif.” Biochem. Biophys. Res. Commun. 285, 1361-1368.

 

158.    Wang X, Yeh S, Wu G, Hsu C, Wang L, and Chang C (2001) “Cloning and characterization of androgen receptor coregulator, ARA267-a in prostate cancer cells.” J. Biol. Chem. 276, 40417-40423.

 

159.    Kuo SM, Huang CT, Blum PB, and Chang C (2001) “Quercetin cumulatively enhances copper induction of metallothionein in intestinal cells.”  Bio.Trace Element Res. 84, 1-10.

 

160.    Heinlein C and Chang C (2002) “Structural and Functional Analysis of the Androgen Receptor.” pp17-56 in Androgens and Androgen Receptor: Mechanisms, Functions and Clinical Application. (Chang C ed). Kluwer, USA.

 

161.    Li M, Richter F, Chang C, Irwin RJ and Huang H.(2002)“Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptor.” BMC Cancer  2:16-23.

 

162.    Miyamoto H, Rahman M, Takatera H, Kang H, Yeh S, Chang H, Nishimura K, Fujimoto N, and Chang C (2002) “A dominant-negative mutant of androgen receptor coregulator, ARA54 inhibits androgen receptor-mediated prostate cancer growth.” J. Biol. Chem. 277, 4609-4617.

 

163.    Heinlein C and Chang C (2002) “Signal Transduction Pathways Modulate Androgen Receptor Transcriptional Activity.” pp 57-90 in Androgens and Androgen Receptor: Mechanisms, Functions and Clinical Application. (Chang C ed). Kluwer, USA.

 

164.    Schinner S, Dellas C, Schroder M, Heinlein C, Chang C, Fischer J and Knepel W (2002) “Repression of glucagon gene transcription by PPARg through inhibition of Pax6 transcriptional activity.” J. Biol. Chem. 277, 1941-1948.

 

165.    Shyr C, Hu YC, Kim ES, and Chang C (2002) “Modulation of estrogen receptor-mediated transactivation by orphan receptor TR4 in breast cancer MCF-7 cells.”  J. Biol. Chem. 277, 14622-14628.

 

166.    Heinlein C, Sampson E and Chang C (2002) “Androgen Receptor Interacting Proteins Co-Activators and Co-Repressors.” pp 91-138 in Androgens and Androgen Receptor: Mechanisms, Functions and Clinical Application. (Chang C ed). Kluwer, USA.

 

167.    Ting H, Yeh S, Nishimura K, and Chang C (2002) “Supervillin associated with androgen receptor and modulates its transcriptional activity.” Proc Natl. Acad. Sci .99, 661-666.

 

168.    Hsing A, Chokkalingam A, Gao Y, Wu G, Wang X, Deng j, Cheng J, Sesterhenn I, Mostofi F, Chiang T, Chen Y, Stanczyk F, and Chang C (2002) “Polymorphic CAG/CAA repeat length in the A1B1/SRC-3 gene and prostate cancer risk: a population-based case-control study.” Cancer Epidemiology, Biomakers and Prevention 11, 337-341.

 

169.    Shyr C, Collins L, Mu XM, Platt KA and Chang C (2002) “Spermatogenesis and testes development are normal in mice lacking the testicular orphan nuclear receptor-2 (TR2).” MCB. 22, 4661-4666.

 

170.    Heinlein C and Chang C (2002) “Nongenomic Androgen Action.” 139-154 in Androgens and Androgen Receptor: Mechanisms, Functions and Clinical Application. (Chang C ed). Kluwer, USA.

 

171.    Wang X, Yang Y, Guo X, Sampson E, Hsu CL, Tsai MY, Wu G, Guo Y and Chang C (2002) “Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator.”  J. Biol. Chem. 277, 15426-15431.

 

172.    Heinlein CA, and Chang C (2002) “Androgen receptor coregulator: an overview.” Endocrine Review. 23, 175-200.

 

173.    Lin HK, Wang L, Hu YC, Altuwaijri S and Chang C (2002) “Phosphorylation-dependent ubiquitination and degradation of AR by Akt requires Mdm2 E3 ligase.” EMBO 21, 1-12.

 

174.    Fu M, Wang C, Wang J, Zhang X, sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua S, Jaffray E, Hay RT, palvino JJ, Janne OA and Pestell R (2002) “Androgen receptor acetylation governs transactivation and MEKK1-induced apoptosis without affecting in vitro sumoylation and transrepression function.” MCB 15, 3373-3388.

 

175.    Thin TH, Kim E, Yeh S, Sampson ER, Chen YT, Collin L, Basavappa R, and Chang C (2002) “Mutations in the helix 3 region of the androgen receptor abrogate ARA70 promotion of 17b-estradiol-induced androgen receptor transactivation.” J. Biol. Chem. 277, 36499-36508.

 

176.    Hsing A, Culig Z, Wang X, Uemura H and Chang C (2002) “The Expanded Poly-Q Length Within AR and AR Coregulator A1B1 And Their Clinical Implications.” pp 245-264 in Androgens and Androgen Receptor: Mechanisms, Functions and Clinical Application. (Chang C ed). Kluwer, USA.

 

177.    Hu YC, Shyr CR, Che S, Mu XM, Kim E and Chang C (2002) “Suppression of estrogen receptor-mediated transcription and cell growth by interaction with TR2 orphan receptor.” J. Biol. Chem. 277, 33571-33579.

 

178.    Collins L and Chang C (2002) “Androgens in Spermatogenesis and Contraception.” pp 299-324 in Androgens and Androgen Receptor: Mechanisms, Functions and Clinical Application. (Chang C ed). Kluwer, USA.

 

179.    Lee Y, Lee H and Chang C (2002) “Recent advances in the TR2 and TR4 orphan receptors of nuclear receptor superfamily.”  JSBMB 1728, 1-17.

 

180.    Sampson E, Yeh S. Miyamoto H, Lee DK, Tsi, MY, Wang X, Hsu CL, and Chang C (2002) “Interaction of cell cycle regulatory proteins with the androgen receptor.” pp 223-238 in Steroid hormones and cell cycle regulation. (Burnstein KL ed). Kluwer, USA.

 

181.    Lin HK, Hu YC, Altuwaijri S and Chang C (2002) “Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells.” J. Biol. Chem. 277, 36570-36576.

 

182.    Lee Y, Lin W, Huang J, Messing E, C Kuo, Wilding G, and Chang C (2002) “Activation of MAP kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor negative prostate cancer cells.” Cancer Research 62, 6039-6044.

 

183.    Itami S. Inui S, Uno H, Pan H, Chang E, Takayasu S, Ye F, Imamura K, Seki T, Ideta R, Aoki H, Adachi K, Price V, Kurata S, Collins L, Heinlein C and Chang C (2002) “Androgens in Dermatology: Hair Loss, Acne, and Other Diseases.” pp 411-476 in Androgens and Androgen Receptor: Mechanisms, Functions and Clinical Application. (Chang C ed). Kluwer, USA.

 

184.    Heinlein CA, and Chang C (2002) “The roles of AR and androgen binding proteins in nongenomic androgen actions.” Mol. Endo. 16, 2181-2187.

 

185.    Yeh S, Tsai MY, Xu Q, Mu X, lardy H, Huang KE, Lin H, Yeh SD, Altuwaijrl S, Zhou X, Xing L, Boyce B, Hung MC, Zhang S, Gan L and Chang C (2002) “Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues.” Proc Natl. Acad. Sci.  99,13498-13503.

 

186.    Ohtsu H, Ishida J, Nagai M, Wang H, Itokawa H, Su C, Shih C, Chiang T, Chang E, Lee Y, Tsai M, Chang C and Lee K (2002) “Antitumor agents 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents.” J. of Medicinal Chemistry 45, 5037-5042.

 

187.    Shih C, Chang E, Zhang Y, Lai C, Su C, Chen Y, Chang H, Chiang T and Chang C (2002) “The use of a flow cytometry analysis in the study of different expression of androgen receptor in human prostate cancer LNCaP and PC-3 cells.” New Taipei Journal of Medicine 4, 151-158.

 

188.    Kang H, Huang KE, Chang S, Ma WL, Lin WJ and Chang C (2002) “Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4."  J. Biol. Chem. 277, 43749-43756.

 

189.    Lin J, Li J, Lee YF, Yeh SD, Altuwaijri S, Ou JH and Chang C (2003) “Suppression of hepatitis B virus core promoter by the nuclear orphan receptor TR4.” J. Biol. Chem. 278, 9353-9360.

 

190.    Yang Y, Wang X, Dong T, Kim E, Lin WJ and Chang C (2003) “Identification of a novel TR4 orphan receptor associated protein (TRA16) as repressor for the selective suppression of TR4-mediated transactivation.” J. Biol. Chem. 278, 7709-7717.

 

191.    Lee DK and Chang C (2003) “Molecular communication between androgen receptor and general transcription machinery.”  JSBMB 84, 41-49.

 

192.    Thin TH, Kim E, Basavappa R, and Chang C (2003) “Isolation and characterization of androgen receptor mutant, AR(M749L), with hypersensitivity to the 17-beta estradiol treatment.” J. Biol. Chem. 278, 7699-7708.

 

193.    Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S and Chang C (2003) “Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 mutant in prostate cancer cells.” J. Biol. Chem. 278, 19619-19626.

 

194.    Rahman MM, Miyamoto H, Kan PY, Lardy H and Chang C (2003) “Inactivation of androgen receptor (AR) coregulator ARA55 leads to an inhibition of AR transactivation and a reduction of the agonist activity of antiandrogens in prostate cancer cells." Proc Natl. Acad. Sci. 100, 5124-5129

 

195.    Lee DK, Li M and Chang C (2003) “The second largest subunit of RNA polymerase II interacts with and enhances transactivation of androgen receptor.” BBRC 302, 162-169.

 

196.    Miyamoto H, Marwah P, Lardy H and Chang C (2003) "3b-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity." Proc Natl. Acad. Sci. 100, 4440-4444.

 

197.    Yang L, Lin HK, Altuwaijri S, Xie S and Chang C (2003) “APPL suppresses androgen receptor transactivation via potentiating Akt activity.” J. Biol. Chem. 278, 16820-16827.

 

198.    Hsu CL, Yeh S, Chen YL, Ting HJ, Hu YC, Hank L, Wang X and Chang C (2003) “The use of phase display technique for the isolation of androgen receptor interacting peptides with F/WXXLF/W and FXXLY new signature motifs.” J. Biol. Chem. 278, 23691-23698.

 

199.    Mu X, and Chang C. (2003) “TR3 orphan nuclear receptor mediates apoptosis through up-regulating E2F1 in human prostate cancer LNCaP cells” J. Biol. Chem. 278, 42840-42845.

 

200.    Kim E, Xie S, Lee YF, Collins L, Hu YC, Shyr CR, Mu XM, Liu NC, Chen YT, Wang PH, and Chang C (2003) “ApoE-TR4 orphan nuclear receptor induces the expression of liver apolipoprotein E/C-I/C-II gene cluster via hepatic control region.” J. Biol. Chem. 278, 46919-46926

 

201.    Lee HJ, Sampson ER, Hsu CL, Chen YT and Chang C (2003) “Androgen receptor.” pp 87-101 in Molecular mechanisms of action of steroid receptors (Marija and Costas Demonacos ed). Research Signpost, India.

 

202.    Chey WY, Chang CH, Pan H, Chang C, Kim BK, Park IS and Chang TM (2003) “Evidence on the presence of secretin cells in the gastric antral and oxyntic mucosa.” Regulatory Peptides 111, 183-190.

 

203.    Yang L, Wang L, Lin HK, Kan P, Xie S, Tsai MY, Wang PH, Chen YT and Chang C (2003) “Interleukin-6 differentially regulates androgen receptor transavtivation via PI3K-Akt, STAT3 and MAPK three distinct signal pathways in prostate cancer cells.” BBRC. 305, 462-469.

 

204.    Lee H, and Chang C (2003) “Recent advances in the androgen receptor action.” Cellular and Molecular Life Sciences. 60, 1613-1622.

 

205.    Inui, S, Lee Y, Chang E, Shyr CR and Chang C (2003) “Differential and bidirectional regulation between TR2/TR4 orphan nuclear receptors and a specific ligand mediated-peroxisome proliferator-activated receptor a (PPARa) in human HaCaT keratinocytes.” J. of Dermatology Science 31:65-71.

 

206.    Mu X and Chang C (2003) “TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3.” The Prostate. 57, 129-133.

 

207.    Heinlein CA, and Chang C (2003) “Induction and Repression of Peroxisome Proliferator-Activated Receptor alpha (PPARa) Transcription by the Coregulator ARA70.” Endocrine 21, 139-146.

 

208.    Cai Y, Dai T, Ao Y, Konishi T, chuang KH, Lue Y, Chang C and Wan Y (2003) “Cytochrome P450 gene are differentially expressed in female and male hepatocyte retinoid X receptor a-deficient mice.” Endocrinology 144, 2311-2318.

 

209.    Kang HY, Tsai MY, Chang C and Huang KE (2003) “Mechanisms and clinical relevance of androgens and androgen receptor action.” Chang Gung Medical J. 26, 388-402.

 

210.    Lee DK and Chang C. (2003) “Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication.” Journal of Clinical and Metabolism of Endocrinology. 88, 4043-4954

 

211.    Nishimura K, Ting HJ, Harada Y, Tokizane T, Nonomura N, Kang HY, Chang HC, Yeh S, Shin M, AozasaK, Okuyama A and Chang C (2003) “Modulation of androgen receptor transactivation by gelsolin: A new identified AR coregulator” Cancer Research. 63, 4888-4894.

 

212.    Altuwaijri S, Lin HK, Chuang KH, Yeh S, Hanchett L, Zhang Y, Tsai MT, Yang L, and Chang C (2003) “Interruption of NFkB Signaling by Androgen Receptor Facilitates TPA-induce apoptosis in an Androgen Sensitive Prostate Cancer Cell Line.” Cancer Research. 63, 7106-7112.

 

213.    Fu M, rao M, Wang C, sakamaki T, Wang J, Vizio DD, Zhang X, Albanese C, Balk S, Chang C. Fan S, Rosen E, Palvimo J, Janne O, Muratoglu S, Avantaggiati ML and Pestell RG (2003) “Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth.” MCB. 23, 8563-8573.

 

214.    Yeh S, Hu YC, Wang PH, Xie C. Xu Q, Zhou X, Tsai MY, Dong Z, and Chang C. (2003) “Abnormal mammary gland development and growth retardation in breast cancer MCF7 cells and female mice lacking androgen receptor.”  J. Experimental Medicine 198, 1899-1908.

 

215.    Ohtsu H, Itokawa H, Su CY, Shih C, Chiang T, Chang E, Lee YF, Chen YT, Chang C, and Lee, KH. (2003) “Antitumor Agents 222. Synthesis and Anti-androgen Activity of New Diarylheptanoids.” Bioorg Med Chem. 17, 5083-5090.

 

216.    Lin H, Hu W, Yang L, Altuwaijri S, Chen YT Kang HY and Chang C (2003) “Suppression vs induction of androgen receptor by the PI3K/Akt pathway in prostate cancer LNCaP cells with different passage numbers.” J. Biol. Chem 19, 50902-50907.

 

217.    Miyamoto H, Rahman MM and Chang C (2004) “Molecular basis for the antiandrogen withdrawal symdrome” J. Cellular Biochemistry. 1, 3-12.

 

218.    Collins L, Lee H, Chen YT, Yeh S and Chang C. (2004) "Androgen receptor in spermatogenesis” Cytogenetic and Genome Research in press

 

219.    Zhang Y, Yang Y, Yeh S and Chang C. (2004) “ARA67 functions as a repressor to suppress androgen receptor transactivation.” MCB. 24, 1044-1057.

 

220.    Hu YC, Wang PH, Hu YC, Yeh S, Xie C, Zhou X, Xu Q, Chao HT, Tsai MY, and Chang C. (2004) “Reduced fertility and defective ovulation in female mice lacking androgen receptor.” Proc Natl. Acad. Sci. In press.

 

221.    Yang L, Yeh SD, Xie S, Altuwaijri S, Ni J, Hu YC, Chen YT, Bao BY, Su CH and Chang C (2004) “Androgen suppresses PML protein expression in prostate cancer CWR22R cells” BBRC in press

 

222.    Heinlein CA, and Chang C (2004) “Androgen receptor in prostate cancer.” Endocrine Review. In press

 

223.    Rahman M, Miyamoto H, and Chang C. (2004) “Androgen Receptor Coregulators in Prostate Cancer Progression: Mechanisms and Clinical Implications.” Clinical Cancer Research. In press.

 

224.    Collins L, Lee YF, Lin WJ, Heinlein CA, Liu NC, Chen YT, Chen Y, Shyr CR, Meshul CK, Uno H, Chou S, Platt KA and Chang C (2004) “Growth retardation and abnormal female maternity in mice lacking testicular orphan nuclear receptor 4” Proc Natl. Acad. Sci. In press

 

225.    Wang L, Hsu CL, Ni J, Wang PH, Yeh S, Ken P and Chang C. (2004) “Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells” MCB. In press.

 

226.    Miyamoto H and Chang C. (2004) “Androgen Deprivation Therapy for Prostate Cancer: Current Status and Future   Prospects.” The Prostate. In press.

 

227.    Chang C, Chen YT, Yeh SD, Xu Q, Guillou F, and Yeh S. (2004) “Infertility with defective spermatogenesis and hypotestosteronemia in mice lacking androgen receptor in Sertoli cells.” Proc Natl. Acad. Sci. In press

 

228.    Xie S, Lin HK, Ni J, Wang L, Yang L, di Sant’Agnese PA, and Chang C. (2004) “Regulation of interleukin-6 mediated P13K activation and neurendocrine diffrentiation by androgen signaling in prostate cancer LNCaP cells.” The Prostate.  In press

 

229.    Litvinov I, Chang C and Isaacs J. (2004) “Molecular characterization of commonly-used human androgen receptor expression vector, pSG5-AR” The Prostate.  In press.

 

230.    Wang L, Lin HK, Hu YC, Mu X, Xie S, and Chang C. (2004) “Glycogen Synthase Kinase 3b Negatively Regulates Androgen Receptor-Dependent Transcription and Cell Growth.” JBC. In press. 

 

231.    Lin H, Hu W, Lee K, and Chang C (2004) “Suppression of androgen receptor transactivation by PTEN tumor suppressor via protein degradation and nuclear translocation.” Cancer Research submitted.

 

232.    Lin H, Xu Q, Yeh S and Chang C (2004) “Insulin resistance with obesity in aging mice lacking androgen receptor” MCB Submitted.

 

233.    Tsai MY, Yeh SD, Yeh S, Xu Q, Zhou X, Lin H, Chiang HS, and Chang C. (2004) “Normal Spermatogenesis and Fertility in Germ Cell-Specific Androgen Receptor Knockout Mice.” Endocrinology. Submitted.

 

234.    Collins L, Lee YF, Lin WJ, Heinlein CA, Liu NC, Chen YT, Chen Y, Shyr CR, Meshul CK, Uno H, Chou S, Platt KA and Chang C (2004) “Priapism with reduced fertility in mice lacking testicular orphan nuclear receptor 4” Proc Natl. Acad. Sci. Submitted.

 

235.    Mu X, Liu NC, Chen YT, Collins L, Kim E, Shyr CR, Lee YF and Chang C. (2004) “Target inactivation of TR4 orphan receptor delays and disrupts late meiotic prophase and subsequent meiotic divisions of spermatogenesis” MCB. Submitted

 

236.    Lin J, Lee YF, Li J, Ou JH, Chuang KH, Altuwaijri S  and Chang C (2004) “Androgen receptor represses hepatitis B virus core promoter via interaction with nuclear receptors TR4 and androgen receptor.” Hematology  Submitted

 

237.    Yang L, Xie S, Altuwaijri S, Ni J, Hu YC, Bao B, and Chang C. (2004) “Induction of androgen receptor gene expression by PI3K/Akt downstream substracts, FKHRL1 and their roles in prostate cancer LNCaP cell apoptosis.”JBC. Submitted.

 

238.    Mu X, Liu Y, Shyr CR, Kim E, Hu YC, Liu NC and Chang C. (2004) “Androgen-induced receptor TR4 is Involved in Attachment of Round Spermatids to Sertoli Cells in Rhesus Monkey and Mice.” Development. Submitted

 

239.    LeeDK, Altuwaijri S, Yang Z, Xu Q, Tsai MY, Yeh S and Chang C. (2004) “Androgen receptor regulates expression of skeletal muscle specific proteins and muscle cell types.” Endocrinology. Submitted.

 

240.    Liu Y, Shyr CR, Kim E, Hu YC, Liu NC and Chang C. (2004) “Reduced viability with hypoglycemia via down regulatation of PEPCK in the newborn and young mice lacking TR4 orphan nuclear receptor” Nature Medicine. Submitted

 

241.    Hu YC,  Yeh S, Yeh SD, Sampson E, Li P,  Hsu CL, Ting H, Lin H, Wang L, Kim E and Chang C (2004) “Functional Domain and Motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.” JBC  Submitted

 

242.    Chuang KH, Lee YF, Lin WJ, Wan Y and Chang C (2004) “Mutual regulation and interaction between androgen receptor and retinoid X receptor.” MCB  Submitted

 

243.    Kim ES, Inui S, Lin D, and Chang C (2004) “Induction of Bcl-2 gene expression by the human TR4 orphan nuclear receptor; a new pathway from nuclear hormone receptor to apoptosis modulator.” J. Biol. Chem. Submitted.

 

244.    Lee Y, and Chang C (2004) “Modulation of the retinoic acid-induced cell apoptosis and differentiation by the human TR4 orphan receptor.” J. Biol. Chem. Submitted

 

245.    Young W, Collins L, and Chang C (2004) “Stage-specific expression of the TR2 orphan receptor during male germ cell development.” Endocrine Submitted.

 

246.    Chang C. (2004) “Functional Analysis the MAP Kinase Target Sites on Androgen Receptor.”JBC. Submitted.

 

247.    Si M, Lai C, Khardori R, Su C, and Chang C (2004) “Differential suppression of estrogen-induced oxidative resistance by 4-hydroxy-tamoxifen and raloxifene in bovine aortic endothelial cells.” J. Biol. Chem. submitted.

 

248.    Su CY, Miyamoto H, Russell B, Lai CC, Chang E, Lin WJ, Yan L, Altuwaijri S, Chen YT, Lee, KH, Shih C, and Chang C. (2004) “Identification of Curcumin analogue JC-15 as a powerful antiandrogen to suppress androgen receptor-mediated prostate cancer growth.” Submitted.

 

249.    Kim E, and Chang C. (2004) “Regulation of Apolipoprotein E Expression by TR4 Orphan Receptor via 5’ Proximal Promoter Region.” Endocrinology Submitted.

 

 

(Abstracts are also available upon requested